With Pfizer Inc.'s oxycodone Troxyca ER still unlaunched after approval last summer and Collegium Pharmaceutical Inc. hammering away for market share with April-cleared Xtampza ER, the quest for a better abuse-resistant, extended-release oxycodone goes on, as does Purdue Pharma LP, selling Oxycontin in the $2.5 billion pain market.